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[57] ABSTRACT 
The invention provides the LCB1 and LCB2 genes of the 
yeast Saccharomyces cerevisiae that encode subunits of the 
enzyme sen'ne palmitoyltransferase (SPT), the ?rst enzyme 
leading to synthesis of the long-base component of the 
sphingolipids. The present speci?cation describes the isola 
tion of the LCB1 and LCB2 genes. The invention further 
relates to methods of using these genes to either inhibit SPT 
activity or to inhibit synthesis of the enzyme. Furthermore, 
the invention relates to methods for constructing strains of S. 
cerevisiae or other organisms that can be used to select and 
to test for compounds that either inhibit SPT activity or to 
inhibit synthesis of the enzyme. 
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METHOD FOR OBTAINING ANTIFUNGAL 
AND HERBICIDAL COMPOUNDS THAT 
TARGET THE FIRST COMMITTED STEP IN 
SHINGOLIPID LONG-CHAIN BASE 
BIOSYNTHESIS 
This application is a continuation of application Ser. No. 
07/906,899 ?led Jun. 30, 1992, now abandoned. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to the isolation of the LCBl and 
LCB2 genes of the year Saccharomyces cervisiae that 
encode subunits of the enzyme serine palmitoyltransferase 
(SPT), the ?rst enzyme leading to synthesis of the long~base 
component of sphingolipids. The invention further relates to 
method of using these genes to either inhibit SPT activity or 
to inhibit synthesis of the enzyme. Furthermore, the inven 
tion relates to methods for construction strains of S. cervi 
siae or other organisms that can be used to select and test for 
compounds that either inhibit SPT activity or to inhibit 
synthesis of the enzyme. 
2. Description of the Background 
Sphingolipids are abundant in the membranes of fungi 
(Brennah, P. 1., & Losel, D. M. 1978. Fungal lipids, in 
Microbial Physiology, Rose, A. H. & Morris, P. G., Eds. 17, 
47—179, Acad. Press.,,N.Y.), animals (Seeley, C. C. and 
Siddiqui, B. 1977; the Glycojungates, Horowitz, M. I. and 
Pigman, W., eds., Acad. Press, N.Y. 1:495), and higher plants 
(Laine, R. a., Hsieh, T. C.-Y., & Lester, R. L. Glycophos 
phocerarnides from plants, in Cell Surface Glycolipids, p.65, 
Am. Chem. Soc. Symp. Ser. 128, Am. Chem. Soc. Wash, 
DC.) 1980. In spite of much e?ort, it has been dif?cult to 
understand the exact biological role(s) of sphingolipids and 
their mode of action at the molecular level. In animals, 
sphingolipids are thought to play a role in such general 
cellular events as cell-to-cell recognition, regulation of cell 
growth, and diiferentiation. The prevalence of sphingolipids 
suggests that they play vital roles in cells and direct proof 
that sphingolipids are essential cellular components has been 
obtained with the discovery of mutants of S. cervisiae that 
absolutely require a sphingolipid long-chain base (see 
below) for growth (Wells, G. B. and Lester, R. L.; J.Biol. 
Chem. 258: pages 10200-10203 (1983)) and viability 
(Pinto, W. J ., Wells, G. B., Williams, A. C., Anderson, K. A., 
Teater, E. C., and Lester, R. L., Fed. Proc. 45: 1826 (1986)). 
sphingolipids are derivatives of ceramides containing 
sugars and sometimes phosphates. Cerarnides usually con 
tain a fatty acid of 20-26 carbons connected via an amide 
linkage to a long-chain base. The major long-chain bases 
and their predominant distribution are: 
Sphingosine (animals) 
CH3(CH2)12CH=CH—CH—CH—CH;OH 
OH NH; 
Phytosphingosine (plants, fungi) 
CH2(CH2)12"CHz—CH—$H-—$H—CH2OH 
OH OH NH; 
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-continued 
The route of sphingolipid biosynthesis is proposed to be: 
‘d all’ NR2 2% 3~ketodihydrosphingosine 
+ 
CO2 L-serine + CoASH 
b. 3 -keto dihydrosphingo sine CH3(CH2)14(|:H — (‘1H — CHZOH 
% OH NH; 
dihydrosphingosine 
+ + 
NADPH NADP+ + H‘r 
O , ? 
c. dihydrosphingosine —2———> phytosphingosine 
cl. long-chain base ceramide 
+ —>> + 
fatty acyl-CoA CoA 
Reaction (a), the ?rst committed step in sphingolipid 
biosynthesis (reviewed in Merrill, A. H. and Jones, D. D. 
1990. Biochemica et Biophysica Acta. 1044:1—12) is cata 
lyzed by serine palinitoyltransferase (SPT, also called 3-ke 
todihydrosphingosine synthetase). This enzyme has been 
shown to occur in the fungus Hansenula ciferri (Snell, E. E., 
Di Mari, S. 1., and Brady, R. N. 1970. Chem. Phys. Lipids, 
5:116~138), in beef liver (Stolfel, W. 1970. Chem. Phys. 
Lipids. 51 139-158), and in the bacterium Bacteroides mela 
ninogenicus (Lev, M., and Milford, A. F. 1973. Arch. Bio 
chem. Biophys. 157:500-508). Other evidence for this reac 
tion comes from our own work in S. cervisiae (Pinto et al., 
1986; Pinto W. 1., Wells, G. W. and Lester, R. L. 1992. J. 
Bacteriol. 174:2575-2581). The enzyme has never been 
purified to homogenity and characterized in any detail 
(reviewed in Merrill, A. H. and Jones, D. D. 1990. Bio 
chemica et Biophysica Acta. 1044:1-12). 
In reaction (d) the long-chain base is attached to a fatty 
acid to form a cerarnide. In all organisms ceramides are 
converted to complex derivatives, the sphingolipids, by the 
addition of polar groups to the l-hydroxyl. The sphingolip 
ids in animals contain various oligosaccharides inked gly 
cosidically to the cerarnide to yield glycosphingolipids and 
also contain choline linked by a phosphodiester bond to 
ceramide to yield the abundant compound sphingomyelin. 
Certain sphingolipids in fimgi and plants differ from the 
sphingolipids in animals because the l-hydroxyl is linked 
through a phosphoryl group to inositol (myo-inositol) rather 
than directly to a sugar. This core structure, inositol-phos 
phorylcerarnide, or inositol-P-ceramide (“IPC”, Smith, S. 
W., and Lester, R. L. 1974. J. Biol. Chem. 249:3395-3405), 
along with mannose-inositol-P-ceramide, (MIPC, ibid) and 
mannose-(inositol-P)2-ceramide (M(IP)2C, (Steiner, S., 
Smith, S. Waechter, C. J ., and Lester, R. L. 1969. Proc. Natl. 
Acad. Sci. USA. 64:1042—1048) collectively constitute the 
sphingolipids in S. cervisiae (Smith, S. W., and Lester, R. L. 
1974. J. Biol. Chem. 249:3395-3405). Phosphoinositol sph 
ingolipids are also a major class of lipids in plants (for 
references see Kaul, K. and Lester, R. L. 1975. Plant 
Physiol, 55:120—129) and parasites (Singh, B. N., Costello, 
C. E., and Beach, D. H. 1991. Arch. Biochem. Biophys. 
286:409-418). 
Because sphingolipids are vital for S. cerevisiae, the 
long-chain base biosynthesis pathway would appear to be a 
good target for antifungal compounds. In fact, sphingolipids 
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may be vital for all organisms that contain them, and 
therefore, any compound that would inhibit long-chain base 
biosynthesis might inhibit growth of an organism that con 
tained sphingolipids. 
Accordingly, there is a need to begin to identify or design 
such inhibitory antifungal compounds to target the long 
chain base biosynthesis pathway, which would appear to be 
a good target for antifungal compounds. Therefore we 
isolated two S. cerevisiae genes, LCB1 (SEQ ID NOS.: 1-3) 
and LCB2 (SEQ ID NOS.: 4-6), that most likely encode 
subunits of SPT. These are the ?rst genes involved in 
long-chain base biosynthesis to be isolated from any organ 
ism. The genes provide a unique opportunity to identify 
compounds that block SPT activity or synthesis in speci?c 
organisms. 
SUMMARY OF THE INVENTION 
One objective of the present invention is to provide the 
LCB1 (SEQ ID NOS.: l-3), and the LCB2 ((SEQ ID NOS.: 
4-6) genes of S. cerevisiae and to demonstrate that they 
provide SPT enzyme activity to a strain that lacks such 
enzyme activity. 
Another objective of the present invention is to provide 
the LCB1 ((SEQ ID NOS.: 1-3), and the LCB2 ((SEQ ID 
NOS.: 4-6), genes of S. cerevisia for use in constructing a 
genetically engineered strain of S. cerevisiae that has 
increased SPT protein and therefore enzyme activity. 
Another objective of the present invention is to provide 
the DNA sequence of the LCB1 ((SEQ ID NOS.: 1-3) and 
LCB2 ((SEQ ID NOS.: 4-6) genes for use as targets for 
antisense or triple-helix~forming oligonucleotides which 
will inhibit the production of SPT protein. 
Another objective of the present invention is to provide 
the DNA sequence of the LCB1 (SEQ ID NOS.: l-3) and 
LCB2(SEQ ID NOS.: 4-6) genes for use in overexpression 
of the genes and subsequent overproduction of the SPT 
enzyme. 
Another objective of the present invention is to provide 
the DNA sequence of the LCB1 ((SEQ ID NOS.: l-3) and 
LCB2 ((SEQ ID NOS.: 4-6) genes for use in isolating the 
homolog of these genes from other organisms. 
Other objectives and advantages of the invention will 
become apparent as the description thereof proceeds. 
In satisfaction of the foregoing objects and advantages, 
the present invention provides the LCB1 ((SEQ ID NOS.: 
l-3) and LCB2 ((SEQ ID NOS.: 4-6) genes and their DNA 
sequence. The genes are shown to restore SPT activity to a 
lcbl((SEQ ID NOS.: l-3)-defective and lcb2((SEQ ID 
NOS.: 4—6)-defective strain, respectively. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 represents a schematic diagram of plasmids car 
rying the LCB1 (SEQ ID NOS.: 1-3) gene of S. cerevisiae. 
FIG. 2 sets forth the DNA sequence of the LCB1 (SEQ ID 
NOS.: 4-6) gene and the predicted protein product. 
FIG. 3 sets forth a comparison of the ‘LCB1 (SEQ ID 
NOS.: 1-3) protein sequence with other proteins that cata 
lyze a chemical reaction that is similar to the one catalyzed 
by SPT. 
FIG. 4 sets forth a comparison of the reaction catalyzed by 
SPT and other enzymes. I 
FIG. 5(A-C) represents a schematic diagram of plasmids 
carrying the LCB2 (SEQ ID NOS.: 4-6) gene of S. cerevi 
siae or portions of the gene. 
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FIG. 6 sets forth the DNA sequence of the LCB2 (SEQ ID 
NOS.: 4-6) gene and the predicted protein sequence. 
FIG. 7 sets forth a comparison of LCB1 (SEQ ID NOS.: 
l-3), LCB2 (SEQ ID NOS.: 4-6), and the S. cerevisiae 
HEMl protein sequences. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The invention relates to the isolation of the LCB1 (SEQ 
ID NOS.: l-3) and LCB2 (SEQ ID NOS.: 4-6) genes of S. 
cerevisiae. 
The present invention provides a DNA sequence LCB1 
having a nucleotide sequence as set forth in FIG. 2. It also 
provides a plasmid comprising the LCB1 sequence accord 
ing to the invention. Particularly preferred is a plasmid 
according to the invention which is the plasmid pTZl8 
LCB1 (SEQ ID NOS.: l-3) containing the LCB1 (SEQ ID 
NOS.: 1-3) sequence. Also, particularly preferred is a plas 
mid according to the invention which is plasmid YIpLCBl-l 
containing the LCB1 sequence. 
In another embodiment the present invention provides a 
host cell line transformed by a plasmid containing the LCB1 
(SEQ ID NOS.: l-3) sequence according to the present 
invention. 
In another aspect the present invention provides a DNA 
sequence LCB2 (SEQ ID NOS.: 4-6) having a nucleotide 
sequence as set forth in FIG. 6. It also provides a plasmid 
comprising the LCB2 (SEQ ID NOS.: 4-6) sequence 
according to the invention. Particularly preferred is a plas 
mid according to the invention which is the plasmid 
pRSLCB2-2 containing the LCB2 (SEQ ID NOS.: 4-6) 
sequence. 
In another embodiment the present invention provides a 
host cell line transformed by a plasmid containing the LCB2 
(SEQ ID NOS.: 4-6) sequence according to the present 
invention. 
The present invention further provides a genetically engi 
neered strain of S. cerevisiae which has increased production 
of Serine Palmitoyltransferase protein and therefore 
increased enzyme activity as compared to the wild type S. 
cerevisiae. 
In another aspect the present invention provides an anti 
sense or triple helix forming oligonucleotide speci?c for the 
LCB1 (SEQ ID NOS.: l-3) sequence, which will inhibit the 
production of Serine Palrnitoyltransferase protein. 
In still another aspect the present invention provides an 
antisense or triple-helic-forming oligonucleotide speci?c for 
the LCB2 (SEQ ID N 08.: 4-6) sequence, which will inhibit 
the production of Serine Palrnitoyltransferase protein. 
The present invention also provides a genetically engi~ 
neered microbial strain transformed by a plasmid compris 
ing either the LCB1 (SEQ ID NOS.: l-3) or LCB2 (SEQ ID 
NOS.: 4-6) sequence, or both the LCB1 (SEQ ID NOS.: 
l-3) and LCB2 (SEQ ID NOS.: 4-6) sequences, which 
overexpresses the gene(s) with which it is transformed and 
subsequently overproduces the Serine Palrnitoyltransferase 
enzyme. 
Also the present invention provides a method for testing 
an oligonucleotide or organic compound for the ability to 
block Serine Palmitoyltransferase activity or synthesis, 
which method comprises: 
exposing the oligonucleotide or the organic compound 
being tested to a host cell or host cell extract, which host cell 
has been transformed to include either a LCB1 (SEQ ID 
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NOS.: l-3) gene or LCB2 (SEQ ID NOS.: 4-6) gene (or 
both genes), and 
testing for an absence of Serine Palmitoyltransferase 
enzyme or its activity, which diminished activity is indicated 
by the absence or lower concentration of sphingolipids. 
The present invention further provides an oligonucleotide 
DNA sequence, which is a complement to either the LCB1 
(SEQ ID NOS.: 1-3) or LCB2 (SEQ ID NOS.: 4-6) 
sequences, or to portions thereof. 
In yet another aspect the present invention provides a 
method of testing for and/or isolating closely related 
sequences (similar to LCB1 (SEQ ID NOS.: 1-3)) which 
comprises 
producing or obtaining an oligonucleotide which is a 
complement to a portion of the LCB1 (SEQ ID NOS.: 1-3) 
gene, and 
using the complement as an oligonucleotide probe by 
‘ exposing a target nucleotide sequence to the said nucle 
otide probe and testing for binding to said probe, and 
optionally 
isolating and separating the nucleotide probe from the 
DNA sequence to which it has bound. 
In still another aspect, the present invention provides a 
method of testing- for and/or isolating closely related 
sequences (similar to LCB2 (SEQ ID NOS.: 4-6)) which 
comprises _ 
producing or obtaining an oligonucleotide which is a 
complement to a portion of the LCB2 (SEQ ID NOS.: 4-6) 
gene, and 
using the complement as an oligonucleotide probe by 
exposing a target nucleotide sequence to the said nucle 
otide probe and testing for binding to said probe, and 
optionally 
isolating and separating the nucleotide probe from the 
DNA sequence to which it has bound. 
The LCB1 (SEQ ID NOS.: 1-3) and LCB2 (SEQ ID 
NOS.: 4-6) sequences according to the present invention, 
plasmids comprising either of the LCB1 (SEQ ID NOS.: 
1-3) or LCB2 (SEQ ID NOS.: 4-6) sequences, transformed 
host cells having a sequence according to the present inven 
tion, and sequences which are complements are all useful in 
screening potential antifungal agents, or for producing 
reagents useful in screen potential antifungal agents, (both 
oligonucleotides and organic chemical agents, which are 
potential antifungal agents may be screened). 
The sequences according to the present invention are also 
useful to provide oligonucleotides which have complemen 
tary DNA sequences, which complementary sequences can 
be used as probes to screen for sequences which are 
homologs of the claimed sequences and/or used in a process 
to isolate and ultimately sequence such homologs of LCB1 
(SEQ ID NOS.: 1-3) or LCB2 (SEQ ID NOS.: 4-6). 
In accordance with present invention, as a preliminary 
step, a mutant strain of S. cerevisiae blocked in sphingolipid 
biosynthesis was obtained. For example, strains of S. cer 
evisiae carrying the mutant allele, lcbl-1, are absolute 
auxotrophs and grow only when a long-chain base (lcb, 
phytosphingosine but not sphingosine) is added to the cul 
ture medium. 
The genes were isolated from a S. cerevisiae genomic 
DNA library by complementation for growth on medium 
lacking a long-chain base (such as phytosphingosine) of an 
lcbl or an lcb2-defective Strain. 
The original lcb mutant MCGA (MATot lcbl-1 inol (J. 
Biol. Chem. 258, 10200-10203 (1983) was crossed with 
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strain W303-1B (MATot ade2-l canl-lOO ura3-l his3-l1,l5 
trpl-l leu2-3,1l2; obtained from R. J. Rothstein, Columbia 
University). Progeny from this cross were backcrossed to 
W303-1B, and several o?spring were selected for further 
study, including strains X2A1B (MATa lcbl-1 ura3-l trpl-l 
his3-11,15). Strain SL1 was derived from strain SJ21R 
(MATa ura3-52 leu2-3,ll2 adel MELl) by replacement of 
the LCB1 allele with a mutant allele that was disrupted by 
inserting a 1.1-kb URA3 DNA fragment at the SalI site of 
LCB1. The LCB1: URA3-disrupted allele was prepared by 
transferring 4.3-kb HindIII-Stul fragment, carrying LCB1, 
from pLCB to pTZ18 (Pharmacia) cleaved with HindIII and 
Smal. The resulting plasmid, pTZl 8-LCB1 was cleaved 
with SalI and ligated with a 1.1-kb URA3 DNA fragment 
having SalI cohesive ends (obtained from pUC-URA3 cut 
with SalI) to yield pTZ18-LCB1::URA3. 
To replace the LCB1 chromosomal allele with the URA3 
disrupted allele, 10 pg of pTZ18-LCB1::URA3 DNA was 
cleaved with Xbal and ClaI, extracted with phenol, phenol 
chloroform, and chloroform and precipitated with ethanol. 
The DNA was transformed into strain SJ21R with selection 
for Ura+ transformants. Replacement of the LCB1 chromo 
somal allele with the URA3-disrupted allele was veri?ed by 
Southern blot analysis. YIpLCBl-l was constructed by 
inserting TRPl of S. cerevisiae, as a 1.4-kb HindIII frag 
mentm into the HindIII site of pTZl8-LCB1. YIpLCBl-l 
was cleaved at its unique BAMHI site located on the 3'side 
of LCB1, and the linear DNA was used to transform strain 
24D5 with selection for Ura+transformants. Integration at 
the expected chromosomal location was veri?ed by South 
ern blotting. Transformants were crossed to strain YPHl 
(MATa ura3-52 lys2-80l ade2-l0l (See, for example, 
Genetics, 122, 19-27 (1989)). 
The plasmid pLCB was isolated from a S. cerevisiae 
genomic DNA library carried in a CEN vector. The 6.44-kb 
vector was pBR322 with a 0.63-kb Sau3A CEN3 DNA 
fragment inserted into the PvuII site of the vector and a 
1.4-kb TRTRPl ARSl fragment inserted into the EcoRI site 
of the vector. The ligations were done with molecules whose 
ends were made blunt ended so that the original restriction 
sites were destroyed. Sau3A genomic DNA fragments of 
8-kb average size from strain X2180 (a/ot gal2/gal2) were 
cloned into the BamHI site of the vector (the library was 
obtained from ZymoGenetics, Seattle, Wash). DNA frag 
ments from pLCB were subcloned into YCpSO (see, Meth 
ods Enzymol, 152, 481-504 (1987)). 
Plasmids were propagated in Escherichia coli DH50t. The 
lob-defective strains were propagated in several media as 
described later in the detailed section which follows. 
For example, to isolate LCB1, strain X2A1B (relevant 
genotype lcbl-1, trpl) was transformed with a genomic 
DNA library which was carried in a vector containing CEN3 
and ARSl, for single-copy propagation in yeast cells, and 
TRPl, for selection of Trp+ yeast that had been transformed 
with the vector. Ten thousand Trp+ transforrnants were 
selected on minimal medium plates containing phytosphin 
gosine but lacking tryptophan. Transformants were pooled 
and reselected on minimal medium plates lacking both 
tryptophan and phytosphingosine. About one per thirty-?ve 
hundred Trp+ colonies was able to grow without added 
phytosphingosine and thus had an Lcb‘” phenotype. 
Plasmid DNA was isolated from several Lcb+ yeast trans 
forrnants and transformed into E. coli with selection for 
ampicillin resistant cells. Plasmid DNA from E. coli trans 
formants was isolated and digested with restriction endonu 
cleases. The pattern of restriction fragments indicated that 
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the original Lcb’" yeast transforrnants all contained the same 
plasmid which carried an insert of about 8 kb. 
To localize the LCB1 gene on the 8 kb DNA insert we 
subcloned parts of the insert into the CEN4 vector YCp50 
and tested the resulting plasmids for their ability to confer a 
Lcb+ phenotype on strain X2A1B. The experiments local 
ized LCB1 to a subclone of 4.0 kb (FIG. 1). 
Further localization of LCB1 was achieved by chromo 
somal disruption. For these experiments the 4 kb insert was 
disrupted at the unique SalI site (FIG. 1) by insertion of the 
URA3 gene of S. cerevisiae to create the lcbl::URA3 
disruption allele. The lcb1::URA3-disruption allele was 
used to replace the wild type LCB1 allele in strain SJ 21R 
(relevant phenotype Lcb+ Ura‘) by homologous recombina 
tion as described in EXAMPLE 2. These procedures pro 
duced a strain, SL1, having the chromosome disrupted at the 
expected SalI site. If this procedure had disrupted the LCB1 
gene then the strain SLlshould require long-chain base 
(phytosphingosine) for growth and, therefore, having an 
Lcb“ phenotype. This expectation was veri?ed because 
strain SL1 had an Lcb‘ phenotype. We conclude that the SalI 
site shown in plasmid YCpSO-LCBl between the PstI and 
Hpal sites is located within the LCB1 gene. 
Genetic complementation analysis was used to verify that 
the lcb1::URA3 disruption mutation in strain SL1 was allelic 
to the original lcbl-l mutation carried in strain X2A1B. 
Strain SL1 was crossed to strain 24D5. The resulting dip 
loids had an Lcb‘ phenotype, suggesting allelism of the 
cloned gene and lcbl. Strong support for allelism would be 
obtained by sporulating these diploids and showing that all 
tetrads give four Lcb‘ spores. However, such diploids failed 
to sporulate under a variety of conditions suggesting that 
sphingolipids are needed for sporulation. An alternative 
genetic approach was used to demonstrate allelism. The 
putative LCB1 allele, carried on the integrating vector 
YIpLCBl-l, was directed to integrate into its homologous 
chromosomal locus as described in EXAMPLE 3. The host 
strain for integration of YIpLCBl was strain 24D5 which 
carried the lcbl-1 mutation. If YIpLCBl-l did indeed carry 
the wild type LCB1 gene then the host strain should have 
this plasmid integrated next to the lcbl-1 allele. When this 
strain is crossed to an LCB1 strain (YPHl) all progeny 
should be Lcb+ since YIpLCB l-l should be tightly linked to 
lcbl-l and there should be little if any recombination events 
that would separate the two alleles. In fourteen four-spored 
tetrads from such a cross, showing 2*:2‘ segregation for the 
Ade, Ura and Leu phenotypes, all spores were Lcb+ indi 
cating that YIpLCBl had been directed to integrate in close 
proximity to the lcbl-1 allele. We conclude that the LCB1 
gene has been cloned and is carried on pTZl8-LCB1 gene 
as claimed. 
To determine if SPT activity was missing in lcbl-defec 
tive strains and to determine if a plasmid carrying LCB1 
restored such activity we assayed membranes for the 
enzyme. The parental strain MC6A contained 54.4 units of 
enzyme activity per mg of protein while the lcbl-defective 
strain X2A1B contained 2.5 units per mg of protein or about 
20 times less enzyme activity that the parental strain: this 
level of activity is at the limit of detection and the actual 
enzyme activity may be lower. The cloned LCB1 allele 
carried in pLCB was able to restore enzyme activity to about 
50% of the wild-type level since three independent trans 
formants of strain X2A1B gave 22.7, 25.6, and 22.8 units of 
enzyme activity per mg of protein. These data support the 
claim that LCB1 encodes the SPT enzyme or a subunit of the 
enzyme. 
Based upon the results of the lcbl::URA3 disruption 
experiments a region surrounding the Sall site shown in FIG. 
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1 was subjected to DNA sequence analysis and the sequence 
was analyzed by computer to locate large open reading 
frames which could encode the LCB1 protein. The sequence 
(FIG. 2) contained a single, large open reading frame, 
encoding 558 amino acids which was oriented in the same 
direction of transcription as the LCB1 mRNA (data not 
shown). This region must code for the LCB1 protein product 
because it is in the correct 5’ to 3' orientation, because a 
URA3 disruption of the open reading frame at the unique 
SalI site created a Lcb‘ phenotype, and because it is geneti 
cally tightly linked to the lcbl-l allele. 
The nucleotide sequence of the open reading frame was 
used to product the anrino acid sequence of the LCB1 
peptide. The results of the prediction are illustrated above 
each codon of the nucleotide sequence (FIG. 2) beginning 
with the ?rst ATG codon at position +1 and ending with the 
stop codon TAA at position +1675. Assuming that this ATG 
codon is the true translation initiation site, the product of the 
open reading frame is a protein of 558 amino acids. Since the 
amino terminus of the LCB1 protein has not been deter 
mined directly it is possible that the amino terminus of the 
actual protein is di?ierent than indicated in FIG. 2. The 
difference could occur either because of post-translational 
processing or because an ATG codon down stream of the one 
shown in FIG. 3 is used as the initiation codon. 
Because SPT activity is present in the membrane fraction 
of lysed cells, we expected the LCB1 protein to be mem 
brane~associated. The hydrophobicity of the deduced protein 
sequence was therefore exarrrined for potential membrane 
spanning regions. According to the 5theory of Kyte, J ., and 
Doolittle, R. F. 1982. J. Mol. Biol. 157:105—132, the Grand 
Average Hydropathy Score (GRAVY) for the predicted 
LCB1 protein is —l.39, a value that places the protein in the 
same class as globular proteins. A globular, rather than 
integral membrane, protein is also predicted by the proce 
dure of Eisenberg, D., Schwartz, E., Komaromy, M., and 
Wall, R. 1984. J. Mol. Biol. 179:125-142. In addition, this 
analysis predicts two very hydrophobic, membrane-associ 
ated helices. Helix I spans amino acid residues 12—32 and 
has the sequence IPIPAFIVTTSSYLWYYFNLV, while 
Helix II spans residues 344-373 and has the sequence 
ATAIDITVGSMATALGSTGGFVLG. 
The predicted amino acid sequence of the LCB1 protein 
shows high similarity to the enzyme S-aminolevulinic acid 
synthase (ALA synthase) whose structural gene has been 
sequenced from many organisms including S. cerevisiae 
(ALSY (SEQ ID NO.: 12), FIG. 3, Urban-Grimal, D., 
Wollard, C., Garnier, T., Dehoux, P., and Labbe-Boise, R. 
1986. Eur: J. Biochem. l56:5ll—519), mouse (ALSM (SEQ 
ID NO.: 10), FIG. 3, Schoenhaut, D. S., and Curtis, P. J. 
1986. Gene 48:55—63) and chicken (ALSC (SEQ ID NO.: 
11), FIG. 3, Riddle, R. D., Yamarnoto, M., and Engel, J. D. 
1989. Proc. Natl. Acad. Sci. USA. 86:792-796). The pre 
dicted LCB1 protein also shows high similarity to the 
Escherichia coli enzymes 2-amino-3-ketobutyrate CoA 
ligase (EKBL (SEQ ID NO.: 8), FIG. 3, Aronson, B. A., 
Ravnikar, P. D., and Somerville, R. L. 1988. Nucleic Acids 
Res. 16:3586) and biotin synthetase (EBIO, FIG. 3, Otsuka, 
A. J., Buoncristiani, M. R., Howard, P. K., Flamm, J., 
Johnson, C., Yamarnoto, R., Uchida, K., Cook, C., Ruppet, 
J., and Matsuzaki, J. 1988. J. Biol. Chem. 
263:19577—19585). 
The similarity of the LCB1 protein to ALA synthase and 
to 2-amino-3-ketobutyrate CoA ligase seems particularly 
signi?cant since these enzymes catalyze a reaction (FIG. 4) 
that is very similar to that catalyzed by SPT. In addition, the 
E. coli 2-amino-3-ketobutyrate CoA ligase uses pyridoxal 
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phosphate as a cofactor (Mukherjee, J. J., Dekker, E. E. 
1987. J. Biol. Chem. 262:14441-14447) as do serine palmi 
toyltransferase (Brady, R. O. and Koval, G. J. 1957. J. Am. 
Chem. Soc. 79:2648—2649) and ALA synthase (Wamich, G. 
R., and Bumham, B. F. 1971. J. Biol. Chem. 
246:6880-6885). The similarity of the amino acid sequences 
(FIG. 3) and the reactions catalyzed by these enzymes (FIG. 
4) argue that the product of LCBl is most likely SPT or a 
catalytic subunit of the enzyme, rather than a regulatory 
protein that regulates transcription of LCBl or the enzy 
matic activity of SPT. 
Besides lcbl-mutant strains, lcb2-mutant strains also lack 
SPT enzyme activity (Pinto, W. 1., Wells, G. W., and Lester, 
R. L. 1992. J. Baterial. 17412575-2581). The LCB2 gene 
was isolated from a S. cerevisiae genomic DNA library of 
complementation for growth on medium lacking phytosph 
ingosine of the lcb2 mutation carried in strain B8238. The 
strain was transformed with the same recombinant DNA 
library that was used for isolation of LCB1. Ura“ transfor 
mants were selected, pooled, and replated on plates lacking 
phytosphingosine to select transforrnants that could grow in 
the absence of phytosphingosine (Lcb+). Plasmid DNA was 
recovered from Lcb+ cells by transformation into E. coli. 
Plasmid DNA isolated from E. coli was analyzed by restric~ 
tion digestion. The pattern of restriction fragments indicated 
that all plasmids carried the same insert of about 7-kb which 
we designated B7 (FIG. 5). 
LCB2 was localized by subcloning and testing the sub 
clones for their ability to complement the lcb2 mutation in 
strain B8238 and allow the strain to grow in the absence of 
phytosphingosine (EXAMPLE 4). These data localized the 
LCB2 gene to a region near the Apal site shown in FIG. 1. 
DNA around this site was sequenced and the sequence was 
scanned by computer in all reading frames. There was only 
one large open reading frame, indicated by the open box at 
the top of FIG. 5. The determined DNA sequence and the 
translated open reading frame representing the putative 
LCB2 protein are indicated in FIG. 6. 
To prove that this open reading was the LCB2 gene we 
used the cloned gene to make a chromosomal deletion allele 
lcb2A3tzURA3 (EXAMPLE 5), as shown in FIG. 5. The 
deletion allele was originally introduced into the diploid 
strain YPH501 and Southern blotting was used to verify that 
the deletion strain carried one normal allele and the deletion 
allele (data not shown). The diploid was sporulated and 
spores were tested for their Lcb phenotype. All 17 four 
spored tetrads showed 2:2 segregation for the Lcb+:Lcb_ 
phenotype and all the Lcb- spores were Ura‘“ as expected for 
a URA3 gene disruption. Thus, the deleted region is needed 
for long-chain base synthesis as would be expected if the 
region was the LCB2 gene. To verify that the putative LCB2 
gene indicated in FIG. 5 is allelic to the authentic LCB2 
gene, we used the integrating vector pRSLCB2-2 
(EXAMPLES 6 and FIG. 5) which only carries the 5' half of 
the putative LCB2 gene. The plasmid was directed, by 
digestion with NaiI, to integrate into the genome of strain 
B5238 (relevant genotype lcb2), at the homologuos NsiI site 
located in the putative LCB2 gene. Integration at the correct 
chromosomal location was veri?ed by Southern blotting 
(data not shown). The strain carrying the integrated plasmid 
was crossed to strain YPH-SOO, diploids were selected, and 
sporulated. Twenty»?ve four-spored tetrads gave 2 Lcb’“:2 
Lcb‘ segregation and all of the Lcb+ spores were Leu‘ while 
the Lcb+ spores were Leu“. These data demonstrate that the 
cloned DNA fragment directs integration at or near the lcb2 
allele carried in strain BS238. Taken as a whole the data 
demonstrate that the LCB2 gene has been cloned. 
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The predicted sequence of the LCB2 protein is shown in 
FIG. 6. The protein contains 561 amino acid residues. Since 
the amino terminus of the LCB2 protein has not been 
determined directly it is possible that the amino terminus of 
the actual protein is different than indicated in FIG. 6. The 
difference could occur either because of post-translational 
processing or because an ATG codon down stream of the one 
shown in FIG. 6 is used as the initiation codon. A membrane 
associated helix is predicted for residues 57 to 77 (PYYIS 
LLTYLNYLILIILGHV) and 443-463 (LGFIVYGVAD 
SPVIPLLLYCP) by the algorithm of Eisenberg et al., 
(1984). 
Comparison of the LCB2 protein sequence against other 
sequences in GenBank using the FASTA search procedure of 
Pearson, W. R. and Lipman, D. J ., 1988, Proc. Natl. Acad. 
Sci. U.S.A. 85:2444-2448 revealed that the sequence was 
homologous to the LCBl protein and to various ALA 
synthases including the one from S. cerevisiae (FIG. 7). In 
addition, the sequence was homologuos to the BAC 
BIOXWF (Genbank) and the ECOKBLTDH (Genbank, 
called EKBL (SEQ ID NO.: 8) in FIG. 3) sequences (data 
not shown). 
The similarity of the LCB2 protein to the ALA synthases 
and to 2-amino-3-ketobutyrate CoA ligase (EKBL FIG. 3, 
ECOKBLTDH Gen Bank) seems particularly signi?cant 
since these enzymes catalyze a reaction (FIG. 4) that is very 
similar to that catalyzed by SPT. In addition, the E. coli 
2-amino-3-ketobutyrate CoA ligase uses pyridoxal phos 
phate as a cofactor (Mukherjee and Dekker, 1987) as do 
serine palmitoyltransferase and ALA synthase. The similar 
ity of the amino acid sequences (FIG. 6) and the reactions 
catalyzed by these enzymes (FIG. 4) argue that the product 
of LCB2 is most likely SPT or a catalytic subunit of the 
enzyme, rather than a regulatory protein that regulates 
transcription of LCB2 or the enzymatic activity of SPT. 
Potential uses of the LCBl and LCB2 genes. 
One use of the genes is to construct strains of S. cerevisiae 
or other organisms or cell lines that can be used to screen for 
inhibitors of SPT enzyme activity or inhibitors of expression 
of the LCBl or LCB2 gene at the transcriptional or trans 
lational level. To construct a strain for screening inhibitors 
of SPT activity, one can use the LCBl and LCB2 genes to 
overproduce their protein product. Overproduction will 
yield a host organism relatively more resistant to SPT 
inhibitors compared to a host that does not overproduce the 
proteins. This principle was ?rst demonstrated in S. cerevi 
siae by Rine, J ., Hansen, W., Hardeman, E., and Davis, R. 
W. 1983. Proc. Natl. Acad. Sci. U.S.A. 80:6750-6754. In the 
case of an inhibitor of transcription or translation, for 
example a triple helix-forming oligonucleotide or an anti 
sense koligonucleotide, one can construct a strain carrying 
multiple copies of the LCBl and LCB2 genes. Multiple 
copies should make the strain more resistant to the inhibitor 
than a strain having only one copy of each gene. A variation 
of this approach could be used for inhibitors of translation 
(an antisense oligonucleotide) in which the LCBl and LCB2 
coding regions would be fused to a strong promoter-en 
hancer region so that a single copy of the fusion genes would 
give high levels of LCBl and LCB2 mRNA. 
Another use of the LCBl and LCB2 genes is to overex 
press them and overproduce their protein product. Such 
overproduction usually makes it possible to purify the 
proteins. Expression and overproduction could be achieved 
in any number of organisms including E. coli, S. cerevisiae, 
or insect cells or other hosts for baculovirus vectors. The 
puri?ed protein could then be used to identify or design 
inhibitors of SPT enzyme activity. 
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Finally, the LCBl and LCB2 genes can be used to isolate 
their homologs from other organisms. Homologs can be 
isolated by complementation of the lcbl and lcb2 mutation 
in appropriate S. cerevisiae host strains such as those pre 
sented in this application. Alternatively, degenerate primers 
for the polymerase chain reaction (PCR) could be designed 
based upon the sequence of LCBl and LCB2 and used to 
prime a PCR reaction using genomic or cDNA from the 
organism whose LCB genes are to be cloned. LCBl and 
LCB2 homologs from particular organisms would enable the 
design of highly speci?c triple~helix forming or antisense 
oligonucleotides or for inhibitors of SPT activity unique to 
a particular organism. 
In the examples the following materials were used: 
S. cerevisiae: The original lcb mutant MC6A (MATa 
lcbl-l inol; Wells and Lester, 1983), was crossed with strain 
W303-1B (MATa ade2-l canl-lOO ura3-l his3-11,15 trpl-l 
leu2-3,ll2; obtained from R. J. Rothstein, Columbia, Univ.). 
Progeny from this cross were backcrossed to W303-1B and 
several offspring were selected for further study including 
strains X2A1B (MATa lcbl-l ura3-1 trpl-l his3-11,15) and 
24D5 (MATot lcbl-l ura3-1 trpl-l leu2-3,ll2 his3-l1,l5). 
Strains YPH 1(MATa ura3-52 lys2-80l ade2-10l,), YPH500 
(MATa ura3-52 leu2-80l“”'b" leu2-A101”""e trp1-A63 his3 
A20 leu2-A1), and YPHSOl (MATa/a ura3-52 leu2-801“'""'“” 
leu2-101"""e trpl-A63 his3A20 leu2-d1 , were obtained from 
Sikorski, R. S. and Hieter, P., 1989, Genetics, 122:19-27. 
Strain BS238 (MATa lcb2 ura3-52 leu2~3,112 adel) was 
from Pinto, W. J ., Srinivasan, B., Shepherd, 8., Schmidt, A., 
Dickson, R. C., and Lester, R. L. 1992. J. Bacteriol. 
174:2565—2574. Strain SJ21R (MATa ura3-52 leu2-3,112 
adel MELl) was described in Dickson, R. C., Wells, G. B., 
Schmidt, A., and Lester, R. L. 1990. Mol. Cell. Biol. 
10:2176—2l81. The YPH strains are sensitive to the long 
chain base phytosphingosine and in order to transform them 
with DNA it is necessary to use 12.5 |.1M phytosphingosine 
and 0.025% tergitol (half of the normal concentrations) in 
selection plates. Likewise, for genetic crosses involving 
YPH strains it is necessary to make the same adjustments for 
dissection plates (minimal medium, Sherman, F., Fink, G. 
R., and Hicks, T. B. 1986. Methods in Yeasts Genetics, Cold 
Spring Harbor Laboratory, Cold Spring Harbor, N. Y.) 
otherwise spores will not germinate. 
Escherichia coli: strain DHSa was used for propagation of 
plasmids. 
Media: PYED contained 1% peptone, 1% yeast extract, 
2% agar (for plates), 50 mM sodium succinate (pH 5), 
inositol (50 mg/l), potassium phosphate monobasic (50 
mg/ml), and 2% or 4% glucose. Minimal medium contained 
l>< Difco Yeast Nitrogen Base without amino acids, 50 M 
sodium succinate (pH 5), 2% glucose, 1.5% agar (for plates), 
inositol (50 mg/ml), valine (150 mg/ml), isoleucine (30 
mg/ml), threonine (200 mg/ml) and these supplements at 20 
mg/l: adenine sulfate, arginine-HCl, histidine-HCl, leucine, 
lysine-HCl, methionine, tryptophan, and uracil. One or more 
supplements were omitted from minimal medium for selec 
tion of yeast transformants. For strains requiring long chain 
base the medium was supplemented with 25 M phytosph 
ingosine (Sigma, St. Louis, Mo.). A 10X stock solution of 
phytosphingosine was prepared by adding 0.25 ml of 100 
M phytosphingosine (dissolved in 95% ethanol) to 99.75 
ml of a 0.5% solution of tergitol (Sigma, St. Louis, Mo.). 
DNA sequencing: Synthetic oligonucleotide primers were 
used for dideoxynucleotide sequencing with Sequenase Ver 
sion 2.0 DNA Polymerase (USB, Cleveland, Ohio) essen 
tially as recommended by the supplier. The LCBl sequence 
(FIG. 2) has been deposited in the Gen Bank and given 
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accession number M63674. The LCB2 sequence (FIG. 6) 
has been deposited in the Gen Bank and given accession 
number M95669. 
Serine palmitoyltransferase activity assays were done as 
described in Buede, R., Rinker~Schaifer, C., Pinto, W. 1., 
Lester, R. L., and Dickson, R. C. 1991. J. Bacteriol. 
173:4325—4332. 
Miscellaneous Procedures—Yeast were transformed by 
the lithium acetate procedure described by Sherman, F., 
Fink, G. R., and Hicks, T. B. 1986. Methods in Yeasts 
Genetics, Cold Spring Harbor Laboratory, Cold Spring 
Harbor, NY. Genetic crosses and tetrad analysis were done 
by standard procedures (ibid). Southern blots were done 
essentially as described by Maniatis, T., Fritsch, E. F., and 
Sarnbrook, J. 1982. Molecular Cloning: A Laboratory 
Manual, Cold Spring Harbor Laboratory, Cold Spring Har 
bor, N.Y. For Southern blots [32P]dATP-labeled probes were 
prepared by the method of Feinberg, A. P., and Vogelstein, 
B. 1983. Anal. Biochem. 13226-13. 
EXAMPLE 1 
The plasmid pLCB (FIG. 1) was isolated from a S. 
cerevisiae genomic DNA library carried in a vector contain 
ing the CEN3 region of S. cerevisiae DNA. The 6.44 kb 
vector was pBR322 with a 0.63 kb Sau3A CEN3 DNA 
fragment inserted into the PvuII site of the vector and a 1.4 
kb TRPlARSl fragment inserted into the EcoRI site of the 
vector. These ligations were done with molecules whose 
ends were made blunt-ended so that the original restriction 
sites were destroyed. Sau3A genomic DNA fragments of 8 
kb average size from strain X2180 (a/a gal2/gal2) were 
cloned into the BamHI site of the vector (the library was a 
gift from Zymogenetics, Seattle, Wash.) To construct 
YCpSO-LCBI, a 4.7 kb StuI fragment from pLCBl contain~ 
ing the LCBl region, was subcloned into the NruI site of 
YCp50 (Rose, M. D. 1987. Meth. Enzymology. 
152:481—504). 
EXAMPLE 2 
Strain SL1 as derived from strain SJ21R by replacement 
of the LCBl allele with a mutant allele that was disrupted by 
inserting a 1.1 kb URA3 DNA fragment from S. cerevisiae 
into the SalI site of LCBl (FIG. 1 shows the SalI site). The 
lcb1::URA3 -disnrpted allele was prepared by ligating a 4.3 
kb HindHI-StuI fragment, carrying LCBl, derived from 
pLCB (FIG. 1) to pTZ18 (Pharrnacia) which had been 
cleaved with the restriction endonucleases HindIH and 
Smal. The resulting plasmid, pTZlS-LCBI (FIG. 1), was 
cleaved with SalI and ligated with a 1.1 kb URA3 DNA 
fragment having SalI cohesive ends to yield pTZ18 
LCB1::URA3. To replace the LCBl chromosomal allele 
with the URA3-disrupted allele, ten micrograms of pTZlS 
LCBl::URA3 DNA was cleaved with XbaI and ClaI, 
extracted with phenol, phenolzchloroform and chloroform, 
and precipitated with ethanol. The DNA was transformed 
into strain SJ21R with selection for Ura+ transformants. 
Replacement of the LCBl chromosomal allele with the 
URA3-disrupted allele was veri?ed by Southern blot analy~ 
sis. Total DNA isolated from SL1 and the non-disrupted 
parental strain SJ21R was cleaved with the restriction endo 
nucleases Nrul and StuI. Following Southern blot analysis, 
the parental strain showed a 4 kb band of hybridization, as 
expected, when the blot was probed with a 32P-labeled NruI 
to StuI DNA probe containing the LCBl region (FIG. 1). If 
the lcb1::URA3-disrupted allele had replaced the wild type 
allele of LCBl in strain SL1 then the Southern blot of strain 
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SL1 should show two bands that hybridize to the 32P~probe 
because URA3 contains a Stul cleavage site. The fragments 
should be 2.1 kb and 3 kb in length. The Southern blot (data 
not shown) contained the two expected bands of hybridiza 
tion indicating that strain SL1 carried the lcbl :zURA3 
disruption allele. 
EXAMPLE 3 
YIpLCB1~1was constructed by inserting TRPl of S. cer 
evisiae, as a 1.4 kb Hind IH fragment, into the Hind HI site 
of pTZl8-LCB1. YIpLCBl-l was cleaved at its unique 
BarnHI site (FIG. 1), located on the 3' side of LCBl, and the 
linear DNA was used to transform strain 24D5 with selec 
tion for Ura+ transforrnants. Integration at the expected 
chromosomal location was veri?ed by southern blotting. 
Transfonnants were crossed to strain YPHl. 
EXAMPLE 4 
Plasmids carrying all of or portions of LCB2 (FIG. 2) 
were constructed using standard molecular cloning tech 
niques as follows. Insert B7 is a 7 kb BarnI-II S. cerevisiae 
DNA fragment cloned into the BamHI site of pRS3l5 
(Sikorski and Hieter, 1989). Insert B7AS is a 4.9 kb BamI-II 
SalI fragment cloned into pRS3l5 at the BamHI-Sall sites of 
the polylinker. Insert 2.3 is a 2.3 kb BamHI-SacI fragment 
cloned into pRS316 (Sikorski and Hieter, 1989) at the 
BamI-II-SacI sites of the polylinker. Insert LCB2-R is a 
4.3-kb EcoRI fragment made blunt-ended by ?lling in the 
ends with the Klenow fragment of DNA polymerase I and 
ligated into the Smal site of pRS3l5. 
EXAMPLE 5 
S. cerevisiae strain LCB25, carrying the lcb2A3::URA3 
allele (FIG. 5), was derived from strain YPHSOl as follows: 
The LCB2-R insert, carried in pIC20R, Marsh, J. L., Er?e, 
M. and Wykes, E. J., 1984, Gene 32:481-485, at the EcoRI 
site of the polylinker, was cleaved with the restriction 
endonucleases Clal and Xbal (FIG. 5), the ends of the 
molecules were made blunt by treatment with the Klenow 
fragment of DNA polymerase I, and the fragment was 
ligated to a 1.1 kb URA3 fragment having blunt ends to give 
the lcb2A3zzURA3 allele (FIG. 5). 
EXAMPLE 6 
The integrating vector pRSLCB2-2 (FIG. 5) was con 
structed by cloning a 2.6-kb BamHI-Apal fragment from the 
B7 insert into the BamHI-Apal region of the polylinker in 
pRS305 (Sikorski and Hieter, 1989). pRS305 carries the 
LEU2 marker gene that was used for selection of transfor 
mants in S. cerevisiae strain B8238. 
DETAILED DESCRIPTION OF THE FIGURES 
FIG. 1 
Structure of Plasmids. The plasmid pLCB carrying the 
LCBl gene is shown. The approximate location of LCBl is 
indicated. Not all restriction endonuclease sites are indicated 
in a given plasmid. The open arrowhead in pTZl8-LCB1 
represents the T7 promoter. DNA sequences are: open box, 
S. cerevisiae; TRPl, a marker gene for selection in S 
cerevisiae; ARSl, a S. cerevisiae autonomous replication 
sequence; CEN3 a centromere for maintenance of a single 
copy of the vector in yeast; BLA and TET confer ampicillin 
and tetracycline resistance in E. coli, respectively. Abbre 
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viations for restriction endonucleases are: B, BamHl, C, 
Clal: E, EcoRI; H, HindIII; Ha, HpaI; K, Kpnl; P, PstI; S, 
SalI; Sa, Sau3A; Sac, Sacl; Sm, Smal; St, StuI; X, Xbal. 
FIG. 2 
DNA sequence of LCBl. The nucleotide sequence of the 
LCBl gene of S. cervisiae is presented along with the 
deduced protein sequence of the 558 amino acids. The 
predicted translation start codon is indicated by +1. 
FIG. 3 
Comparison of the deduced amino acid sequence of LCBl 
to other proteins. The protein sequences of LCBl and the 
mouse (ALSM ((SEQ ID. NO.:10)), chicken (ALSC ((SEQ 
ID. NO.:11)), and yeast (ALSY ((SEQ ID. NO.:12)) 5-ami 
nolevulinic acid synthases were compared using the proce 
dure of Pearson and Lipman (1988) and aligned for maxi 
mum similarity. The 2-arnino-3-ketobutyrate CoA ligase 
(EKBO ((SEQ ID. NO.:8)) and the biotin synthetase (EBIO 
((SEQ ID. NO.:7)) sequences were identi?ed and aligned by 
using the FASTA algorithm (ibid). Colons (:) represent 
identity between residues while dots (.) denote conservative 
replacements by similar residues. Insertions made during the 
alignment optimization process are indicated by dashes (—). 
FIG. 4 
Comparison of the reactions catalyzed by serinenpalmi 
toyltransferase, ALA synthase, and 2-amino-3ketobutyrate 
CoA ligase. 
FIG. 5 
Structure of Plasmids. A restriction map of the 7 kb 
BamHI fragment carrying the LCB2 gene is shown at the top 
of the ?gure and the approximate location of LCB2 and the 
direction of transcription are indicated. Not all of the cutting 
sites for a particular restriction endonuclease are indicated. 
A. Portions of the region carrying LCB2 were tested for their 
ability to complement the Leb- phenotype of an lcb2 
defective strain. E. Structure of a deletion allele. C. Struc 
ture of the chromosomal insert carried in pRSLCB2-2. 
Vector sequences are not shown. Abbreviations for restric 
tion endonucleases are: A, ApaI; B, BamHl; C, Clal; E, 
EcoRI; Ns, NsiI; Sa, SalI; S, SacI; Sn, SnaBl; Sp, Sspl; X, 
Xbal. 
FIG. 6 
DNA sequence of LCB2. The nucleotide sequence of the 
LCB2 gene of S. cervisiae is presented along with the 
deduced protein sequence of the 561 amino acids. Numbers 
on the right side of the ?gure indicate amino acid residues 
while numbers on the left indicate nucleotides. The A of the 
predicted ATG initiation codon has been designated as +1. 
FIG. 7 
Comparison of the predicted LCBl ((SEQ ID. NO.:13) 
and LCB2 ((SEQ ID. NO.:14) protein sequences with each 
other (identical residues indicated by an asterisk above the 
sequence) and with the ALA synthase of S. cervisiae 
(HEM1$Yeast ((SEQ ID. NO.:15)). Asterisks below the 
sequence indicate amino acids that are identical in all three 
sequences while dots (.) indicate amino acids that are similar 
in the three sequences. Dashes (—) indicate gaps in the 
sequence introduced to improve alignment. 
5,583,030 
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The invention now being fully described it will be appar 
ent to one of ordinary skill in the art that many changes and 
modi?cations can be made thereto without departing from 
the spirit or scope of the invention as set forth therein. The 
foregoing description of the speci?c embodiments will so 
fully reveal the general nature of the invention that others 
can, by applying current knowledge, readily modify and/or 
16 
adapt for various applications such speci?c embodiments 
without departing from the generic concept and therefore 
such adaptations are intended to be comprehended within 
the meaning and range of equivalents of the disclosed 
embodiments. It is to be understood that the phraseology or 
terminology employed herein is for the purpose of descrip 
tion only and not of limitation. 
SEQUENCE LISTING 
( I )GENERAL INFORMATION: 
( i i i )NUMBER OF SEQUENCES: 15 
( 2 ) INFORMATION FOR SEQ ID NO:1: 
( i )SEQUENCE CHARACTERISTICS: 
(A )LENGTI-I: 333 
( B )TYPE: Nucleic Acid 
( C ) STRANDEDNESS: single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: polynucleoLide 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NOzl: 
CGCGTATTTT TTTTTTTTTG AGGCGCCATG ATTTCTTACA CGGTTTCTTT TTTTTTTCCT 60 
TCTTTCCTTC TTGCTTCTCT GCTAACAAAT TTTTCACTCA TTCTTTTTTA TAGGGGCATA 120 
TTGCTGCGGT TAACTGTAGT GAACGAAAGT AAGATTGAGA AAATATAGTA CTTAAGAAAA 180 
AGAAAAGGAA AAATAAAAAA AATTCTTTTC AACATCATCG AGTAGCACAG TATAAGAGCG 240 
CTCTAACCTT CTGCCTGGCC TCCAATATAC ACATTTTGCT CGTGTAGGGT TATTTATCCT 300 
TTTTTCTTCC TTCCCACCCA AAAAAAAAAA GCA 333 
( 2 ) INFORMATION FOR SEQ ID NO:2: 
( i )SEQUENCE CHARACTERISTICS: 
(A)I_.ENGTH:I674 
( B ) TYPE: nucleic acid 
( C ) STRANDEDNESSI single 
( D )TOPOLOGY: linear 
( i i )MOLECULE TYPE: polypeptide 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:2: 
ATG GCA CAC T CCA GAG GTT TTA CCC AAA TCA T CCG T CCG GCA 48 
MET Ala His Ile Pro Glu Val Leu Pro Lys Ser Ile Pro Ile Pro Ala 
5 10 I5 
TTT ATT GTT ACC ACC TCA TCG TAC CTA TGG TAC TAC TTC AAT CTG GTG 96 
Phe Ile Val Thr Thr Ser Ser Tyr Leu Trp Tyr Tyr Phe Asn Leu Val 
20 25 30 
TTG ACT CAA C CCG GGA GGC CAA TTC C GTT TCG TAC ATC AAG AAA I44 
Leu Thr Gln Ile Pro Gly Gly Gln Phc Ile Val Ser Tyr Ile Lys Lys 
35 40 45 
TCG CAT CAT GAC GAT CCA TAC AGG ACC ACG GTT GAG ATA GGG CTT T 192 
Ser His His Asp Asp Pro Tyr Arg Thr Thr Val Glu Ilc Gly Leu Ile 
50 55 60 
TTA TAC GGG ATC TAT TAC TTG TCC AAG CCA CAA CAG AAA AAG AGT 240 
Leu Tyr Gly Ilc Ile Tyr Tyr Lcu Ser Lys Pro Gln Gln Lys Lys Ser 
65 70 75 80 
CTT CAA GCA CAG AAG CCC AAC CTA TCG CCC CAG GAG T GAC GCG CTA 288 
Leu Gln Ala Gln Lys Pro Asn Leu Ser Pro Gln Glu Ile Asp Ala Leu 
85 9O 95 
T GAG GAC TGG GAG CCC GAG CCT CTA GTC GAC CCT TCT GCC ACC GAT 336 
Ile Glu Asp Trp Glu Pro Glu Pro Leu Val Asp Pro Ser Ala Thr Asp 














